Metastatic Renal Cancer Clinical Trial
Official title:
Phase II Study of Oral PRednisone 5 mg Bid Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of Vascular Endothelial Growth Factor Receptor-tyrosine Kinase Inhibitors
This is a multicenter prospective study that includes all patients with metastatic Renal Cell
Cancer (RCC) pre- treated with VEGFR TKI in eight Italian cancer centers.
Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil
in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice
daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs
will be self-administered orally, continuously from Day 1 (Visit 2) until progression of
disease, unacceptable toxicity, death or discontinuation for any other reason.
A treatment cycle consists of 28 days.
Title Phase II study of oral PRednisone 5 mg bid plus EVerolimus in patients with metastatic
renal cell cancer after failure of vascular endothelial growth factor receptor-tyrosine
kinase inhibitor (PREV study).
Short Title/ Acronym PREV Protocol Code IRST189.04 Phase Phase 2 Study Design This is a
multicenter prospective study that includes all patients with metastatic RCC pre- treated
with VEGFR TKI in eight Italian cancer centers.
Study Duration 2 years of recruitment and 1 year of follow-up Study Center(s) multi-center: 8
centers involved
Objectives Primary objective:
To evaluate the safety and tolerability of prednisone 5 mg bid and everolimus 10 mg/day in
RCC.
Secondary objectives:
To evaluate the activity and the clinical outcome of these patients.
Exploratory objectives:
To evaluate the influence of prednisone on trough concentration of everolimus and correlation
with the incidence of side effects, in particular stomatitis and non-infectious pneumonitis.
Infiammation markers such as pentraxin 3 (PTX3), IL-6, TGF-β and neutrophil-lymphocyte ratio
will be correlated with clinical outcome (ORR, PFS, OS).
Number of Subjects 42 subjects Diagnosis and Main Inclusion Criteria Patients with mRCC who
failed at least one VEGFR TKI.
Main Inclusion Criteria:
- Patients with renal cell carcinoma who failed at least one VEGFR TKI
- Patients with adequate bone marrow function
- Patients with adequate liver function
- Patients with adequate renal function Diagnosis and Main Inclusion Criteria (continued)
Main exclusion criteria:
- CNS disease OR patients with presence or history of central nervous system (CNS)
lymphoma
- Patients receiving chronic, systemic treatment with corticosteroids or another
immunosuppressive agent (except corticosteroids with a daily dosage equivalent to
prednisone ≤ 20 mg for adrenal insufficiency). However, patients receiving
corticosteroids must be on a stable dose for ≥ 4 weeks prior to the first dose of
everolimus. Topical or inhaled corticosteroids are permitted.
- Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus,
temsirolimus) or to its excipients
- Patients with uncontrolled hyperlipidemia (≥ Grade 3 hyperlipidemia despite optimal
supportive medical therapy)
- Patients with an active, bleeding diathesis
- Previous organ transplantation
- Patients who have any severe and/or uncontrolled medical conditions or other conditions
that could affect their participation in the study Study Product, Dose, Route, Regimen
and duration of administration Everolimus is formulated as tablets of 5-10 mg strength,
blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed
to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10
mg tablet or two 5 mg tablets). Both drugs will be self-administered orally,
continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity,
death or discontinuation for any other reason.
A treatment cycle consists of 28 days. Reference therapy Not applicable Statistical
Methodology This is a multicenter prospective study that includes all patients with
metastatic RCC pre- treated with VEGFR TKI in eight Italian cancer centers.
The study will be analyzed on an intent-to-treat basis. Secondary parameters will be analyzed
exploratively for the intent-to-treat population.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01457131 -
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
|
Phase 1 | |
Terminated |
NCT02837757 -
Everolimus Modulation of Anti-tumor T CD4 Immune Responses
|
N/A | |
Recruiting |
NCT05796973 -
Measuring Oncological Value of Exercise and Statin
|
Phase 3 | |
Recruiting |
NCT03630692 -
Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs
|
||
Terminated |
NCT01160445 -
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
|
Phase 2 | |
Recruiting |
NCT04316520 -
Ketogenic Diet for Patients Receiving First Line Treatment for Metastatic Renal Cell Carcinoma
|
N/A | |
Terminated |
NCT01273181 -
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
|
Phase 1/Phase 2 | |
Completed |
NCT02086734 -
Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma
|